Corcept Therapeutics Incorporated
CORT
$115.70
$1.721.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 55.33% | -18.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 55.33% | -18.42% | |||
| Cost of Revenue | 40.86% | 13.28% | |||
| Gross Profit | 55.59% | -18.82% | |||
| SG&A Expenses | 7.94% | 11.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.16% | 8.53% | |||
| Operating Income | 183.26% | -1,205.44% | |||
| Income Before Tax | 202.72% | -551.21% | |||
| Income Tax Expenses | 122.73% | 9.90% | |||
| Earnings from Continuing Operations | 235.35% | -230.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 235.35% | -230.77% | |||
| EBIT | 183.26% | -1,205.44% | |||
| EBITDA | 186.04% | -1,126.03% | |||
| EPS Basic | 233.84% | -229.63% | |||
| Normalized Basic EPS | 201.79% | -548.24% | |||
| EPS Diluted | 220.00% | -249.78% | |||
| Normalized Diluted EPS | 190.62% | -617.60% | |||
| Average Basic Shares Outstanding | 0.90% | 0.71% | |||
| Average Diluted Shares Outstanding | 13.36% | -12.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||